GlaxoSmithKline settles drug-marketing case for $3 billion

The British pharmaceutical giant agrees to pay a record healthcare-fraud settlement for promoting a number of drugs for uses not approved by federal regulators. California will get $46 million.GlaxoSmithKline, the maker of the popular depression drugs Paxil and Wellbutrin, agreed to plead guilty to federal charges and pay $3 billion in the largest healthcare-fraud settlement in U.S. history.

Read the whole article on LA Times - Health

More from LA Times - Health